Explore
1st Central European Conference for Advanced Therapy and Immunotherapy. Book of Abstracts
0 Ungluers have
Faved this Work
Login to Fave
This gathering brings together leading minds from academia, clinical sites, and research institutions across Central Europe to address shared challenges in rare diseases and advanced therapies. The European Union estimates that between 6,000 and 8,000 rare diseases affect approximately 30 million people across the region, representing around 6-8% of the population. These conditions are often chronic, progressive, and life-threatening, significantly impacting patients' quality of life. On a local level, over half a million people in the Czech R. alone are affected by rare diseases. Despite these numbers, many patients are still waiting for an accurate diagnosis. The number of newly identified rare diseases continues to rise, alongside well-known challenges such as delays in diagnosis. The leading experts in Advanced Therapy Medicinal Products (ATMPs) from the European Union (EU) are significantly contributing to research across the entire ATMP life-cycle. These contributions span multiple stages, from initial discovery and development to clinical trials, manufacturing, regulation, and post-market surveillance. Their research addresses key challenges in the field, such as improving the efficacy, safety, and scalability of gene therapies, cell therapies, and tissue-engineered products.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 8 times via unglue.it ebook links.
- 8 - pdf (CC BY-NC-ND) at munispace.muni.cz.
Keywords
- ATMP
- CREATIC
- innovative therapies
- rare diseases
- thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders
Editions